Fate Therapeutics (FATE) Net Equity Issued and Repurchased (2012 - 2021)

Fate Therapeutics (FATE) has 8 years of Net Equity Issued and Repurchased data on file, last reported at -$31000.0 in Q4 2021.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to -$31000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was -$301000.0 (down 100.61% YoY) and the FY2021 annual result came in at $411.7 million, up 118.1% from the prior year.
• Net Equity Issued and Repurchased advanced to -$31000.0 in Q4 2021, from -$270000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $173.1 million in Q3 2019 to a low of -$270000.0 in Q3 2020.
• A 5-year average of $51.5 million and a median of $23.0 million in 2017 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2018 — Net Equity Issued and Repurchased slumped 100.53% — and 2019, when it surged 44.49%.
• Tracing FATE's Net Equity Issued and Repurchased over 5 years: stood at $46.0 million in 2017, then tumbled by 100.53% to -$245000.0 in 2018, then surged by 44.49% to -$136000.0 in 2019, then tumbled by 98.53% to -$270000.0 in 2020, then surged by 88.52% to -$31000.0 in 2021.
• The last three Net Equity Issued and Repurchased figures came in at -$31000.0 (Q4 2021), -$270000.0 (Q3 2020), and $50.0 million (Q2 2020), per Business Quant data.